1 of 1
Story summary
- Eli Lilly and Company plans to acquire Abivax for €15 billion ($17.5 billion), valuing Abivax at nearly double its current market capitalization.
- Abivax's stock rose about 30% on reports of the acquisition.
- The deal aligns with Eli Lilly's strategy to expand its inflammatory bowel disease portfolio.
- Analysts say the transaction could face a three-month regulatory review in France.
